Dr. Mark Reding, MD

NPI: 1336223866
Total Payments
$607,358
2024 Payments
$73,220
Companies
15
Transactions
500
Medicare Patients
525
Medicare Billing
$55,639

Payment Breakdown by Category

Consulting$301,738 (49.7%)
Other$252,383 (41.6%)
Travel$43,634 (7.2%)
Food & Beverage$9,267 (1.5%)
Education$335.04 (0.1%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $301,738 69 49.7%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $216,648 87 35.7%
Travel and Lodging $43,634 172 7.2%
Honoraria $35,735 11 5.9%
Food and Beverage $9,267 151 1.5%
Education $335.04 10 0.1%

Top Paying Companies

Company Total Records Latest Year
Bayer Healthcare Pharmaceuticals Inc. $112,213 131 $0 (2024)
GENZYME CORPORATION $89,455 44 $0 (2024)
Novo Nordisk Inc $86,036 47 $0 (2024)
Shire North American Group Inc $74,931 84 $0 (2019)
CSL Behring $64,839 41 $0 (2024)
Takeda Pharmaceuticals U.S.A., Inc. $47,597 29 $0 (2023)
BIOVERATIV THERAPEUTICS INC. $44,694 30 $0 (2021)
BioMarin Pharmaceutical Inc. $22,450 22 $0 (2024)
Genentech USA, Inc. $22,132 18 $0 (2024)
HEMA Biologics, LLC $18,960 30 $0 (2024)

Payment History by Year

Year Amount Transactions Top Company
2024 $73,220 66 GENZYME CORPORATION ($18,508)
2023 $58,831 37 GENZYME CORPORATION ($23,813)
2022 $106,551 72 GENZYME CORPORATION ($28,753)
2021 $69,959 38 Takeda Pharmaceuticals U.S.A., Inc. ($28,192)
2020 $45,459 28 CSL Behring ($17,160)
2019 $94,319 95 Bayer HealthCare Pharmaceuticals Inc. ($35,644)
2018 $69,497 46 Bioverativ Therapeutics Inc. ($24,067)
2017 $89,522 118 Shire North American Group Inc ($37,535)

All Payment Transactions

500 individual payment records from CMS Open Payments — Page 1 of 20

Date Company Product Nature Form Amount Type
12/31/2024 BioMarin Pharmaceutical Inc. Consulting Fee Cash or cash equivalent $2,967.18 General
12/06/2024 Genentech USA, Inc. Consulting Fee Cash or cash equivalent $1,900.00 General
12/06/2024 Genentech USA, Inc. Food and Beverage In-kind items and services $128.91 General
12/04/2024 GENZYME CORPORATION ALTUVIIIO (Biological) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $2,909.00 General
Category: Hematology
11/14/2024 HEMA Biologics, LLC SevenFact (Biological) Travel and Lodging Cash or cash equivalent $269.00 General
Category: Hematology
11/14/2024 HEMA Biologics, LLC SevenFact (Biological) Food and Beverage In-kind items and services $97.50 General
Category: Hematology
11/14/2024 HEMA Biologics, LLC SevenFact (Biological) Food and Beverage In-kind items and services $72.53 General
Category: Hematology
11/14/2024 HEMA Biologics, LLC SevenFact (Biological) Travel and Lodging Cash or cash equivalent $44.26 General
Category: Hematology
11/14/2024 HEMA Biologics, LLC SevenFact (Biological) Food and Beverage In-kind items and services $38.32 General
Category: Hematology
11/11/2024 HEMA Biologics, LLC SevenFact (Biological) Food and Beverage In-kind items and services $76.72 General
Category: Hematology
11/09/2024 HEMA Biologics, LLC SevenFact (Biological) Consulting Fee Cash or cash equivalent $5,000.00 General
Category: Hematology
11/09/2024 HEMA Biologics, LLC SevenFact (Biological) Travel and Lodging Cash or cash equivalent $8.60 General
Category: Hematology
11/08/2024 HEMA Biologics, LLC SevenFact (Biological) Food and Beverage In-kind items and services $100.75 General
Category: Hematology
11/01/2024 Novo Nordisk Inc Consulting Fee Cash or cash equivalent $8,776.25 General
11/01/2024 Novo Nordisk Inc Travel and Lodging In-kind items and services $500.10 General
11/01/2024 Novo Nordisk Inc Travel and Lodging In-kind items and services $281.37 General
11/01/2024 Novo Nordisk Inc Food and Beverage In-kind items and services $262.68 General
11/01/2024 Novo Nordisk Inc Travel and Lodging In-kind items and services $48.00 General
10/30/2024 SANOFI-AVENTIS U.S. LLC Consulting Fee Cash or cash equivalent $3,559.50 General
10/16/2024 GENZYME CORPORATION ALPROLIX (Biological) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,870.00 General
Category: Hematology
10/16/2024 GENZYME CORPORATION ALTUVIIIO (Biological) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $1,870.00 General
Category: Hematology
10/04/2024 HEMA Biologics, LLC SevenFact (Biological) Travel and Lodging Cash or cash equivalent $457.96 General
Category: Hematology
09/27/2024 GENZYME CORPORATION Consulting Fee Cash or cash equivalent $6,648.00 General
09/27/2024 GENZYME CORPORATION Food and Beverage In-kind items and services $224.23 General
09/05/2024 BioMarin Pharmaceutical Inc. ROCTAVIAN (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $944.00 General
Category: Hemophilia A

Medicare Billing by Year

Year Procedures Beneficiaries Services Submitted Medicare Paid
2023 3 86 105 $62,514 $10,138
2022 4 101 119 $66,291 $12,060
2021 8 162 186 $82,966 $18,912
2020 10 176 194 $59,288 $14,529
Total Patients
525
Total Services
604
Medicare Billing
$55,639
Procedure Codes
25

All Medicare Procedures & Services

25 procedure records from CMS Medicare Utilization

HCPCS Description Setting Year Patients Services Charges Medicare Paid Ratio
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2023 38 50 $32,314 $5,021 15.5%
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes Facility 2023 17 20 $13,985 $2,683 19.2%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2023 31 35 $16,215 $2,434 15.0%
99215 Established patient office or other outpatient visit, 40-54 minutes Facility 2022 43 51 $29,625 $5,332 18.0%
99214 Established patient office or other outpatient visit, 30-39 minutes Facility 2022 30 40 $16,892 $2,730 16.2%
99223 Initial hospital inpatient care per day, typically 70 minutes Facility 2022 15 15 $10,125 $2,294 22.7%
99205 New patient office or other outpatient visit, 60-74 minutes Facility 2022 13 13 $9,649 $1,703 17.6%
99215 Established patient outpatient visit, total time 40-54 minutes Facility 2021 41 51 $25,071 $5,924 23.6%
99205 New patient outpatient visit, total time 60-74 minutes Facility 2021 22 22 $15,354 $3,105 20.2%
99223 Initial hospital inpatient care, typically 70 minutes per day Facility 2021 18 19 $12,831 $2,989 23.3%
99222 Initial hospital inpatient care, typically 50 minutes per day Facility 2021 22 23 $10,513 $2,450 23.3%
99214 Established patient outpatient visit, total time 30-39 minutes Facility 2021 22 26 $9,608 $1,911 19.9%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2021 14 21 $5,115 $1,186 23.2%
99443 Physician telephone patient service, 21-30 minutes of medical discussion Facility 2021 12 13 $1,714 $814.79 47.5%
99213 Established patient outpatient visit, total time 20-29 minutes Facility 2021 11 11 $2,760 $533.50 19.3%
99223 Initial hospital inpatient care, typically 70 minutes per day Facility 2020 18 20 $12,615 $3,222 25.5%
99443 Physician telephone patient service, 21-30 minutes of medical discussion Facility 2020 30 31 $3,685 $1,964 53.3%
99222 Initial hospital inpatient care, typically 50 minutes per day Facility 2020 13 14 $6,002 $1,531 25.5%
99205 New patient office or other outpatient visit, typically 60 minutes Facility 2020 11 11 $7,250 $1,485 20.5%
99233 Subsequent hospital inpatient care, typically 35 minutes per day Facility 2020 11 15 $4,827 $1,244 25.8%
99232 Subsequent hospital inpatient care, typically 25 minutes per day Facility 2020 16 19 $4,348 $1,099 25.3%
99442 Physician telephone patient service, 11-20 minutes of medical discussion Facility 2020 25 28 $2,177 $1,065 48.9%
99214 Established patient office or other outpatient, visit typically 25 minutes Facility 2020 19 19 $6,481 $1,014 15.6%
99215 Established patient office or other outpatient, visit typically 40 minutes Facility 2020 12 14 $6,463 $987.76 15.3%
99213 Established patient office or other outpatient visit, typically 15 minutes Facility 2020 21 23 $5,440 $917.37 16.9%

About Dr. Mark Reding, MD

Dr. Mark Reding, MD is a Internal Medicine healthcare provider based in Minneapolis, Minnesota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1336223866.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Reding, MD has received a total of $607,358 in payments from pharmaceutical and medical device companies, with $73,220 received in 2024. These payments were reported across 500 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($301,738).

As a Medicare-enrolled provider, Reding has provided services to 525 Medicare beneficiaries, totaling 604 services with total Medicare billing of $55,639. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.

Practice Information

  • Specialty Internal Medicine
  • Other Specialties Hematology & Oncology
  • Location Minneapolis, MN
  • Active Since 10/24/2006
  • Last Updated 01/04/2013
  • Taxonomy Code 207R00000X
  • Entity Type Individual
  • NPI Number 1336223866

Products in Payments

  • ADVATE (Biological) $63,477
  • Jivi (Drug) $50,033
  • Idelvion (Biological) $38,741
  • Kogenate FS (Drug) $27,667
  • NO PRODUCT DISCUSSED (Drug) $26,370
  • ALTUVIIIO (Biological) $21,706
  • SevenFact (Biological) $18,879
  • ELOCTATE (Biological) $14,059
  • HEMGENIX (Biological) $12,775
  • VONVENDI (Biological) $10,200
  • ALPROLIX (Biological) $9,517
  • Kovaltry (Drug) $8,518
  • HEMLIBRA (Biological) $8,271
  • ADYNOVATE (Biological) $8,052
  • Hemlibra (Biological) $6,552
  • Novoeight (Drug) $6,490
  • ROCTAVIAN (Drug) $5,594
  • Non-Covered Product (Drug) $5,280
  • Non-Covered $5,047
  • NovoSeven RT (Drug) $4,655

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Internal Medicine Doctors in Minneapolis